Pamplona

• A PHASE 1B, OPEN-LABEL, DOSE ESCALATION WITH AN EXPANSION TRIAL OF A IN COMBINATION WITH B OR A PLUS STANDARD OF CARE IN PATIENTS WITH XXX C … Ended recruitment
  2025-521582-27-00 3 2025-07-03 XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended recruitment
  2024-519417-57-00 5 2025-06-25 Thyroid eye disease
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516815-26-00 5 2025-05-30 Chronic rhinosinusitis with nasal polyps
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study) … Ended recruitment
  2024-513511-27-00 4 2025-05-29 HR-negative/HER2-negative resectable stage I TNBC.
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Ended recruitment
  2024-512504-19-00 1 2025-05-28 solid tumors
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended recruitment
  2024-515494-95-00 4 2025-05-26 Moderate to Severe Atopic Dermatitis (AD)
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI … Ended recruitment
  2023-505601-16-00 5 2025-04-22 Chronic Migraine
• Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended recruitment
  2024-516063-89-00 5 2025-04-10 Metastatic Pancreatic Ductal Adenocarcinoma
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (anti­IL­33 mAb) in participants with chronic rhinosi … Ended recruitment
  2024-515576-12-00 4 2025-03-20 Respiratory tract diseases
• A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni … Ended recruitment
  2024-513970-23-00 4 2025-02-27 Previously Untreated Chronic Lymphocytic Leukemia
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended recruitment
  2024-514137-38-00 4 2025-02-04 Severe refractory idiopathic inflammatory myopathies (IIM)
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien … Ended recruitment
  2023-504420-26-00 4 2025-01-13 Bladder Cancer
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously … Ended recruitment
  2024-512147-23-00 10 2024-11-21 Chronic Lymphocytic Leukemia
• A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended recruitment
  2023-510525-15-00 4 2024-11-18 active antineutrophilic cytoplasmic antibody (ANCA) associated vasculi
• Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer Ended recruitment
  2024-511358-36-00 4 2024-11-11 Molecularly Categorized Muscle Invasive Bladder Cancer
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer

Showing 409–432 of 821 trials